ConductScience.org, home

Paper41585138

The roles of CD24-Sec14 like lipid binding 2 (SEC14L2) axis in the neoplastic progression of oral squamous cell carcinomas.

Chang SR and 6 others. J Dent Sci, 2026. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. The roles of CD24-Sec14 like lipid binding 2 (SEC14L2) axis in the neoplastic progression of oral squamous cell carcinomas. Papers, record 41585138. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41585138

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The roles of CD24-Sec14 like lipid binding 2 (SEC14L2) axis in the neoplastic progression of oral squamous cell carcinomas.
PubMed
Journal
J Dent Sci
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-01-28
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chang SRShi-Rou
2Chou CHChung-Hsien
3Liu CJChung-Ji
4Chang KWKuo-Wei
5Pan JHJian-Hua
6Yen SLSheng-Lin
7Lin SCShu-Chun

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References39

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116824727CD24 plays an important role in the carcinogenesis process of the pancreas.Biomed Pharmacother2006https://conductscience.org/library/papers/16824727PubMed
237664387Utility of CD44/CD24 in the Outcome and Prognosis of Oral Squamous Cell Carcinoma: A Systematic Review.Cureus2023https://conductscience.org/library/papers/37664387PubMed
337598003Modulating Treg stability to improve cancer immunotherapy.Trends Cancer2023https://conductscience.org/library/papers/37598003PubMed
41319065Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.Proc Natl Acad Sci U S A1992https://conductscience.org/library/papers/1319065PubMed
538313430Surprising magic of CD24 beyond cancer.Front Immunol2023https://conductscience.org/library/papers/38313430PubMed
634434192Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis.Front Immunol2021https://conductscience.org/library/papers/34434192PubMed
718413748Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA.Cancer Res2008https://conductscience.org/library/papers/18413748PubMed
838881902From mechanism to therapy: the journey of CD24 in cancer.Front Immunol2024https://conductscience.org/library/papers/38881902PubMed
937021226miR-146a participates in the regulation of cancer stemness of oral carcinoma cells.J Dent Sci2023https://conductscience.org/library/papers/37021226PubMed
1031406301CD24 - a novel 'don't eat me' signal.Nat Rev Cancer2019https://conductscience.org/library/papers/31406301PubMed
1138622125Single cell analysis unveils B cell-dominated immune subtypes in HNSCC for enhanced prognostic and therapeutic stratification.Int J Oral Sci2024https://conductscience.org/library/papers/38622125PubMed
1239233744Risk Factors of Oral Squamous Cell Carcinoma with Special Emphasis on Areca Nut Usage and Its Association with Clinicopathological Parameters and Recurrence.Int J Surg Oncol2024https://conductscience.org/library/papers/39233744PubMed
1337711538Expression of CD24 as Cancer Stem Cell Marker in the Diagnosis of Oral Squamous Cell Carcinoma - A Prospective Study.Ann Maxillofac Surg2023https://conductscience.org/library/papers/37711538PubMed
1423511563Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas.Br J Cancer2013https://conductscience.org/library/papers/23511563PubMed
1521710320CD24 interacts with and promotes the activity of c-src within lipid rafts in breast cancer cells, thereby increasing integrin-dependent adhesion.Cell Mol Life Sci2012https://conductscience.org/library/papers/21710320PubMed
1624302991miR-146a enhances the oncogenicity of oral carcinoma by concomitant targeting of the IRAK1, TRAF6 and NUMB genes.PLoS One2013https://conductscience.org/library/papers/24302991PubMed
1731345390Establishment of syngeneic murine model for oral cancer therapy.Oral Oncol2019https://conductscience.org/library/papers/31345390PubMed
1827853649CD24 blunts oral squamous cancer development and dampens the functional expansion of myeloid-derived suppressor cells.Oncoimmunology2016https://conductscience.org/library/papers/27853649PubMed
1936341328Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer.Front Immunol2022https://conductscience.org/library/papers/36341328PubMed
2039223142The disruption of NEAT1-miR-125b-5p-SLC1A5 cascade defines the oncogenicity and differential immune profile in head and neck squamous cell carcinoma.Cell Death Discov2024https://conductscience.org/library/papers/39223142PubMed

See all 39 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41585138

GET https://conductscience.org/api/papers/v1/41585138/references?page=2